Abstract
The objective of this study is to evaluate the predictive performance of several models to predict drug clearance in children ≤5 years of age. Six models (allometric model (data-dependent exponent), fixed exponent of 0.75 model, maturation model, body weight-dependent model, segmented allometric model, and age-dependent exponent model) were evaluated in this study. From the literature, the clearance values for six drugs from neonates to adults were obtained. External data were used to evaluate the predictive performance of these models in children ≤5 years of age. With the exception of a fixed exponent of 0.75, the mean predicted clearance in most of the age groups was within ≤50% prediction error. Individual clearance prediction was erratic by all models and cannot be used reliably to predict individual clearance. Maturation, body weight-dependent, and segmented allometric models to predict clearances of drugs in children ≤5 years of age are of limited practical value during drug development due to the lack of availability of data. Age-dependent exponent model can be used for the selection of first-in-children dose during drug development.
Similar content being viewed by others
References
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.
Gibaldi M. Gastrointestinal absorption: Physicochemical considerations. In: Biopharmaceutics and clinical pharmacokinetics. 3rd ed. Philadelphia: Lea and Febiger; 1984.
McNammara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmaSci. 2002;4:1–8.
Blanco JG, Harrison PL, Evans WE, et al. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Disp. 2000;28:379–82.
Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam. 1998;15:45–51.
Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev. 1998;19:423–8.
Mahmood I. Dose selection in children: allometry and other methods. In: Pediatric pharmacology and pharmacokinetics. Rockville: Pine House Publishers; 2008. p. 184–216.
Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41:959–98.
Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet. 2002;41:1077–94.
Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2000;2:article 3 (1-7).
Hayton WL, Kneer J, de Groot R, Stoeckel K. Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants. Antimicrob Agents Chemother. 1996;40:567–74.
Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984;15:1071–121.
Mahmood I. Introduction to allometry. In: Interspecies pharmacokinetic scaling: principles and application of allometric scaling, pp:23-38; Pine House Publishers, Rockville, MD; 2005.
Cella M, Zhao W, Jacqz-Aigrain E, Burger D, Danhof M, Della PO. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454–64.
Santen G, Horrigan J, Danhof M, Della Pasqua O. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255–62.
Anand KJ, Anderson BJ, Holford NH, NEOPAIN Trial Investigators Group, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101:680–9.
Anderson BJ. Pediatric models for adult target-controlled infusion pumps. Paediatr Anaesth. 2010;20:223–32.
Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth. 2011;21(3):302–8.
Wang C, Sadhavisvam S, Krekels EH, Dahan A, Tibboel D, Danhof M, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33:523–34.
Wang C, Peeters MY, Allegaert K, van Blussé van Oud-Alblas HJ, Krekels EH, Tibboel D, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012;29:1570–81.
Wang C, Allegaert K, Peeters MY, Tibboel D, Danhof M, Knibbe CA. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2014;77:149–59.
Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331–45.
Guidance for Industry: Clinical Investigation of Medicinal Products in the Pediatric Population. U.S. Department of Health and Human Services and ICH, 2000.
Mahmood I. Allometric exponents and population pharmacokinetics: a single or body weight dependent exponents. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville, MD, USA; Pine House Publishers, 2013; pp:121-137.
Mahmood I. Prediction of drug clearance in preterm and term neonates: different exponents for different age groups. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville, MD, USA; Pine House Publishers, 2013; pp:88-109.
Mahmood I. Prediction of clearance in children from adult clearance: allometric scaling versus exponent 0.75. In: Pharmacokinetic allometric scaling in pediatric drug development, pp41-55, 2013; Pine House Publishers, Rockville, MD.
Mahmood I. Prediction of drug clearance in children (≤5 years) by Boxenbaum coefficient methods. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville, MD, USA; Pine House Publishers, 2013; pp:64-77
Brody S. Bioenergetics and growth, with special reference to the efficiency complex in domestic animals. 1945; London: Hafner Press, New York, and MacMillan Publishers.
Hayssen V, Lacy RC. Basal metabolic rates in mammals: taxonomic differences in the allometry of BMR and body mass. Comp Biochem Physiol. 1985;81A:741–54.
West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–6.
Kozłowski J, Konarzewski M. Is West, Brown and Enquist’s model of allometric scaling mathematically correct and biologically relevant? Funct Ecol. 2004;18:283–9.
Kozłowski J, Konarzewski M. West, Brown and Enquist’s model of allometric scaling again: the same questions remain. Funct Ecol. 2005;19:739–43.
Painter PR. The fractal geometry of nutrient exchange surfaces does not provide an explanation for 3/4-power metabolic scaling. Theor Biol Med Model. 2005;2:30.
Petit G, Anfodillo T. Plant physiology in theory and practice: an analysis of the WBE model for vascular plants. J Theor Biol. 2009;259:1–4.
Glazier DS. Beyond the ‘3/4-power law’: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev Camb Philos Soc. 2005;80:611–62.
White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology. 2007;88:315–23.
Packard GC, Birchard GF. Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol. 2008;211(Pt 22):3581–7.
Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010;99:2927–33.
Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metab Drug Interact. 2009;24:57–81.
West D, West BJ. Physiologic time: a hypothesis. Phys Life Rev. 2013;10:210–24.
Bentley LP, Stegen JC, Savage VM, et al. An empirical assessment of tree branching networks and implications for plant allometric scaling models. Ecol Lett. 2013;16:1069–78.
Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight and age. Ther Drug Monitor. 2007;29:271–8.
Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006;61:545–57.
Peeters MY, Allegaert K, Blussé van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet. 2010;49:269–75.
Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet. 2006;45:1–11.
Edginton AN, Shah B, Sevestre M, Momper JD. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin Pharmacokinet. 2013;52:693–703.
Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013;167:926–32.
Mahmood I. Prediction of drug clearance in children 3 months and younger: an allometric approach. Drug Metabol Drug Interact. 2010;25:25–34.
Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. 2011;71:88–94.
Mahmood I. Response to the comments of Professors Anderson & Holford. Br J Clin Pharmacol. 2011;72(3):521–3.
Mahmood I. Evaluation of sigmoidal maturation and allometric models: prediction of propofol clearance in neonates and infants. Am J Ther. 2013;20:21–8.
Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res. 1991;20:1–116.
Wieser W. A distinction must be made between the ontogeny and the phylogeny of metabolism in order to understand the mass exponent of energy metabolism. Respir Physiol. 1984;55:1–9.
McMohan TA, Bonner JT. Proportions and size. In: On size and life. New York: Scientific American Library; 1983. p. 25–67.
Box GEP, Draper NR. Empirical model building and response surfaces. New York: John Wiley & Sons; 1987. p. 24.
Conflict of Interest
The authors do not have any financial or conflict of interest. The views expressed in this article are those of the authors and do not reflect the official policy of the FDA or any private enterprise. No official support or endorsement by the FDA or any private enterprise is intended or should be inferred.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 1890 kb)
Rights and permissions
About this article
Cite this article
Mahmood, I., Staschen, CM. & Goteti, K. Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several Models. AAPS J 16, 1334–1343 (2014). https://doi.org/10.1208/s12248-014-9667-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9667-7